Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bd7dd0b0d0dbdf18f7857b59f6eb32a46> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bd7dd0b0d0dbdf18f7857b59f6eb32a46 NCIT_P378 "NCI" @default.
- Bd7dd0b0d0dbdf18f7857b59f6eb32a46 type Axiom @default.
- Bd7dd0b0d0dbdf18f7857b59f6eb32a46 annotatedProperty IAO_0000115 @default.
- Bd7dd0b0d0dbdf18f7857b59f6eb32a46 annotatedSource NCIT_C143162 @default.
- Bd7dd0b0d0dbdf18f7857b59f6eb32a46 annotatedTarget "An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis." @default.